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ABSTRACT
Background:  Nearly  350  million  persons  worldwide  are  chronically  infected  with 
hepatitis B virus (HBV). Ubiquitin (Ub) is a highly conserved small regulatory protein, 
ubiquitous in eukaryotes, that usually serves as a signal for the target protein that is 
recognised and degraded in proteasomes . The Ub-mediated processing of antigens is 
rapid and efficient and stimulates cell-mediated immune responses. Accordingly, Ub-
mediated processing of antigens has been widely used in chronic-infection and cancer 
studies to improve immune response.
Objectives: Many clinical trials have shown that DNA vaccine potency needs to be great-
ly enhanced. Here, we report a new strategy for designing an HBV DNA vaccine using 
the ubiquitin (Ub) sequence. The aim of this study was to investigate a novel DNA vac-
cination, based on the expression of HBV core antigen (HBcAg), fused to Ub to enhance 
DNA vaccine potency.
Materials and Methods: Mouse ubiquitin fused to the HBcAg gene and cloned into the 
eukaryotic vector pcDNA3.1 (-). BALB/c mice were immunized with recombinant pUb-
HBcAg or pHBcAg DNA vaccine. Lymphocyte proliferation assay, intracellular IFN-γ as-
say, CTL cytotoxicity assay, and antibody assay were performed to analyze the cellular 
and humoral immune responses to our DNA constructs.
Results: HBcAg was expressed effectively in the COS-7 cells that were transiently trans-
fected with pUb-HBcAg. Strong anti-HBc IgG responses were elicited in mice that were 
immunized with pUb-HBcAg. The endpoint titers of anti-HBc peaked at 1:656100 on the 
42nd day after the third immunization. pUb-HBcAg stimulated greater lymphocyte 
proliferation and induced higher levels of IL-2 and IFN-γ and a greater percentage of 
HBcAg-specific CD8+ T cells in mice than pHBcAg. In the CTL assay, the specific lysis 
rate reached 56.5% at an effector:target ratio of 50:1 in mice that were immunized with 
pUb-HBcAg.
Conclusions: pUb-HBcAg elicits specific anti-HBc responses and induces HBc-specific 
CTL responses in immunized BALB/c mice. Our results imply that Ub can be used as a 
molecular adjuvant that enhances the potency of DNA vaccines.
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1. Background
An  estimated  350  million  persons  worldwide  are 
chronically infected with hepatitis B virus (HBV). HBV Hepat Mon. 2011;11(8):620-628
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infection is a major global public health problem. 
Approximately 600,000 deaths each year are attributed to 
acute or chronic HBV infection (1).   Although some antiviral 
drugs  are  extremely  well  tolerated  and  suppress  HBV 
replication effectively, they rarely eliminate intranuclear 
viral covalently closed circular DNA (2). Therefore, it is 
necessary to develop an alternative, effective therapeutic 
approach for chronically infected patients. The antigen-
encoding  DNA  vaccine,  which  can  effectively  induce 
humoral and cellular immune responses, has become 
an attractive immunization strategy against a variety of 
pathogens, including HBV (3-5). A prophylactic vaccine 
that based on hepatitis B surface antigen is an effective 
way of reducing the global incidence of hepatitis (6), but 
it does not work therapeutically (7). HBV core antigen 
(HBcAg) possesses unique immunological features. 
Patients  who  successfully  clear  the  virus  usually  have 
efficient  HBcAg-specific  cytotoxic  T  lymphocyte  (CTL) 
responses (8, 9). Plasmid DNA that encodes HBcAg elicits 
humoral and cellular responses in many animal models 
(5, 10, 11). Therapeutic DNA vaccination is a promising 
strategy  for  controlling  chronic  infections.  However, 
this approach has not been as successful as initially 
anticipated for chronic hepatitis B. The application of 
DNA vaccines in humans has been limited due to their 
low  immunogenicity  (12).  Many  attempts  have  been 
made to enhance the potency of DNA vaccines, including 
codelivery  of  a  cytokine  (13)  and  insertion  of  certain 
sequences that enhance immune responses, such as 
cytokine and chemokine genes, into the vector (14, 15).
It is generally accepted that the primary cause of 
viral persistence during HBV infection is an inadequate 
antiviral  response  to  viral  antigens.  Individuals  who 
are chronically infected with HBV generally have low to 
undetectable CTL responses to HBV antigens. Specific 
CD8+ T cells function as CTLs, eliminating HBV (16-18). 
Antigen presentation to CD8+ T cells is mediated by 
MHC  class  I  molecules,  expressed  on  the  surface  of 
antigen-presenting cells. Prior to such presentation, 
antigens must be ubiquitinated and processed into 
suitable antigenic peptides by the ubiquitin-proteasome 
system (UPS) (19-21). The UPS is a highly selective ATP-
dependent proteolytic system in all eukaryotic cells that 
underlies antigen presentation. Ubiquitin (Ub), a highly 
conserved, 76-amino-acid polypeptide that is expressed 
in all eukaryotes, is a part of the UPS. The attachment of 
ubiquitin to a protein is the initial signal for its targeted 
degradation. When a protein is fused to ubiquitin, its 
degradation by the proteasome and presentation can 
be  rapided,  resulting  in  effectively  induced  immune 
responses. This strategy has been applied to DNA 
vaccines to improve immune responses by enhancing 
the production of antigenic peptides that are presented 
by MHC class I molecules (20-22). 
2. Objectives
In  the  study,  we  constructed  expression  plasmids 
encoding mutant Ub-fused HBcAg and demonstrated 
that this fusion DNA vaccine induces humoral and 
cellular immune responses against HBV.
3. Materials and Methods
3.1. Cell Line and Plasmids
COS-7  cells  were  maintained  in  Dulbecco’s  modified 
Eagle’s  medium  (Invitrogen,  Gaithersburg,  MD,  USA), 
supplemented  with  10%  fetal  bovine  serum  (Gibco, 
USA), 100 U/ml penicillin, and 100 μg/ml streptomycin. 
The H-2d mastocytoma cell line P815/c (expressing HBV 
c antigen) was preserved in our lab. The pADR plasmid, 
containing full-length HBV DNA, was provided by Prof. 
Yuan Wang, Shanghai Institute of Biochemistry and Cell 
Biology,  Chinese  Academy  of  Sciences.  The  eukaryotic 
vector pcDNA3.1 (-) was provided by Prof. Huaidong Song, 
Ruijin Hospital, Shanghai Jiao Tong University School of 
Medicine.
3. 2. Plasmid Construction and Preparation
We  used  pcDNA3.1  (-)  as  our  expression  vector  in 
eukaryotic  cells  to  construct  two  plasmids:  pcDNA3.1 
(-) -Ub-HBcAg and pcDNA3.1 (-) -HBcAg. To construct the 
Ub-HBcAg fusion plasmid, the gene encoding mutant 
ubiquitin,  whose  C-terminal  Gly  residue  was  replaced 
with  Ala,  was  amplified  by  PCR  from  genomic  DNA 
from BALB/c mouse liver using primers A and B (23). The 
HBcAg gene, whose N-terminal Met residue was replaced 
with  Arg  according  to  the  N-end  rule,  was  amplified 
from the pADR plasmid by PCR using primers C and D. 
The primers are shown in Table Ub-HBcAg was spliced 
by overlap extension by PCR with primers A and D. The 
purified  Ub-HBcAg  fragment  was  inserted  into  EcoRI/
HindIII-digested pcDNA3.1 (-).
To construct the HBcAg DNA vaccine, the HBcAg gene 
was  PCR-amplified  from  pADR  using  primer  E  with  a 
BamH I site and the antisense primer F with a Hind III site. 
The PCR product was digested with BamHI/Hind III and 
ligated into pcDNA3.1 (-). All plasmids were confirmed 
by restriction enzyme digestion and sequence analysis. 
Plasmids  were  grown  in  Escherichia  coli  DH5α and 
purified using an endotoxin-free purification kit (Qiagen, 
Germany). The purified plasmids were resuspended in 
sterile PBS to 500 μg/ml.
3. 3. In Vitro Transfection, Western Blotting
For  transfection,  COS-7  cells  (5  ×  106  cells/ml)  were 
used to seed 6-well plates in DMEM supplemented with 
10% FBS and incubated for 24 h at 37°C in a humidified 
incubator, 5% CO2. Cells were transiently transfected with 
pUb-HBcAg, pHBcAg, or pcDNA3.1 (-) using Lipofectamine 
2000 (Invitrogen, USA) per the manufacturer. Forty-
eight  hours  after  transfection,  cells  were  harvested  to 
analyze HBcAg by western blot, as described elsewhere 
(24). Mouse monoclonal anti-human HBcAg (Santa Cruz, 
USA) was used as the primary antibody, and horseradish 
peroxidase-conjugated goat anti-mouse IgG was used as 
the secondary antibody.Hepat Mon. 2011;11(8):620-628
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3.4. RT-PCR
In order to detect expression of the DNA vaccines in 
our  eukaryotic  system,  we  extracted  total  RNA  from 
transfected cells and analyzed it by RT-PCR. For each 
PCR reaction, 2 μl of cDNA product of the reverse-
transcription  reaction  was  used  as  the  template.  The 
PCR primers were as follows: Ub-HBcAg forward primer: 
5′-CGCAGAATTCATGCAGATCTTCGTGAAG-3′ and reverse 
primer:5′-GCGAAGCTTCTAACATTGAGATTCCCGAG-3′;   
HBcAg  forward  primer:  5′GATAGGATCCATGGACATTG
ACCCGTAT–3′ and reverse primer: 5′-GCGAAG 
CTTCTAACATTGAGATTCCCGAG–3′, and the housekeeping 
gene β-actin, forward primer: 5′-CATCTCTTGCTCGAACA-3′ 
and reverse primer: 5′-ATCATGTTTGAG ACCTTCAACA-3′. 
The PCR comprised the following steps: 94°C for 10 min 
and 32 cycles of 94°C for 60s, 54°C for 45s, and 72°C for 
120s. Finally, the reactions were incubated at 72°C for 10 
min. The PCR products were examined by agarose gel 
electrophoresis.
3. 5. Mice and DNA Vaccination
Female BALB/c mice (H-2d),  6-8  weeks  old,  were 
acquired from Shanghai Experimental Animal Center of 
Chinese Academy of Sciences and kept under pathogen-
free conditions. The animal experiments were approved 
by  the  institutional  ethical  committee  of  the  Sixth 
People’s  Hospital,  Shanghai  Jiaotong  University.  Mice 
were divided into 5 groups, with 8 mice in each group. 
To increase the efficiency of the gene transfer, the tibialis 
anterior muscle was injected with a total of 100 μl of 0.5% 
aethocaine per mouse. After 24 h, 100 μg pUb-HBcAg, 50 
μg pUb-HBcAg, 100 μg pHBcAg, 50 μg pHBcAg, or 100 μg 
pcDNA3.1(-) was injected into the same muscle in 200 μl 
of PBS. The mice were immunized intramuscularly on 
Days 0, 14, and 28.
3. 6. Detection of HBcAg-Specific IgG
Blood  was  collected  on  Days  0,  14,  28,  and  42  after 
primary immunization from anesthetized mice by 
retro-orbital bleeding. Serum anti-HBc was measured by 
enzyme-linked immunosorbent assay (ELISA) (Diagnostic 
Reagent  Center  of  Shanghai  Municipal  Infectious 
Diseases Hospital, Shanghai, China) in 96-well microtiter 
plates  coated  with  HBcAg.  Serum  was  serially  diluted 
in  PBS  with  5%  nonfat  milk  (starting  from  1:100)  and 
incubated in microtiter plates for 1 hour at 37°C. Plates 
were  washed,  and  horseradish  peroxidase-conjugated 
goat  anti-mouse  IgG  (1:1000)  was  added  to  the  wells 
and incubated at room temperature for 1 hour. After 
extensive washing, the plates were incubated at room 
temperature for 30 min with 100 μl of substrate in the 
presence of hydrogen peroxide. The absorbance at 450 
nm was measured. Endpoint titers were defined as the 
highest serum dilution that resulted in an absorbance 
value 2 times greater than that of negative control sera.
3.7. Lymphocyte Preparation and Lymphocyte 
Proliferation Assay
Mice  were  anesthetized  and  sacrificed  2  weeks 
after  the  last  immunization,  and  their  spleens  were 
homogenized over 200 gauge nylon mesh. Splenocytes 
were  collected,  treated  with  lysis  buffer  to  eliminate 
red cells, washed, and resuspended in RPMI-1640 with 
10%  FBS.  Lymphocytes  were  derived  from  splenocytes 
using  nylon  wool  columns.  Single-cell  suspensions  of 
lymphocytes (5 × 105 cells/well) were grown in 96-well 
plates,  stimulated  in  vitro  with  10  μg/mL  MBP-HBcAg 
(purified in our laboratory) (25), and incubated at 37°C in 
5% CO2 for 72 h. Cultures were incubated with 10 μL CCK-8 
solution (Beyotime Institute of biotechnology, Haimen, 
China) for 4 h at 37ºC. The absorbance was read at 450 
nm.
3.8. Measurement of Cytokine Production In Vitro
To determine whether T helper cells were activated, 
we measured cytokines (IL-2, IFN-γ, IL-4, and IL-10) that 
reflected the Th1 and Th2 responses. Splenocytes from 
mice  in  each  group  were  cultured  in  96-well  culture 
plates  in  the  presence  of  10  μg/mL  MBP-HBcAg  for  4 
days,  and  the  supernatants  were  harvested.  Cytokines 
Gene Name Nucleotide Sequence (5'→3' )
Restriction
Enzyme Site
Ub A: CGCAGAATTC
a
ATGCAGATCTTCGTGAAG EcoR I
B: ATTCTTTATACGGGTCAATGTCTCT
b
AGC
c
ACCTCTCAGGCGAAGGACCAGG
HBcAg C: CCTGGTCCTTCGCCTGAGAGGTGCT
c
AGA
b
GACATTGACCCGTATAAAGAAT Hind III
D: GCGAAGCTT
a
CTAACATTGAGATTCCCGAG
HBcAg d E: GATAGGATCC
a
ATGGACATTGACCCGTAT BamH I
F: GCGAAGCTTC
a
TAACATTGAGATTCCCGAG Hind III
Table . Primers of Ubiquitin and HBcAg
a Restriction enzyme site
b The Ub C-terminal glycine had been replaced with alanine
c HBcAg with a modified N-terminal methionine residue was replaced by arginine
d For the construction of pHBcAg plasmid, the HBcAg gene was PCR-amplified with primers Hepat Mon. 2011;11(8):620-628
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were  measured  using  commercial  ELISA  kits,  per  the 
manufacturer’s  protocol  (R&D  Systems,  Minneapolis, 
MN, USA). Data are expressed as pg/ml.
3.9. Measurement of Intracellular Cytokines in 
Proliferating T Cells
IFN-γ  production  was  measured  by  intracellular 
staining  and  flow  cytometry.  Spleen  cells  from 
immunized  mice  were  plated  in  96-well  plates  and 
stimulated with MBP-HBcAg (final concentration 10 μg/
mL) for 4 days at 37°C in a humidified atmosphere, 5% CO2. 
Proliferating T cells were suspended in complete RPMI 
1640 and stimulated for 6 h in the presence of 25 μg/mL 
phorbol 12-myristate 13-acetate, 1 μg/mL ionomycin, and 
1.7  μg/mL  monensin  (Sigma,  USA).  After  being  washed 
with  PBS,  the  cells  were  stained  with  FITC-conjugated 
anti-CD8°C mAb (eBioscience, USA) for 30 minutes at 4°C, 
washed with PBS, fixed with 4% paraformaldehyde, and 
permeabilized with PBS containing 0.5% saponin (both 
from BD Shanghai, China). Cells were incubated with PE-
labeled anti-interferon-γ (IFN-γ) (eBioscience, USA) for 30 
minutes at 4°C, washed with PBS, and analyzed by flow 
cytometry.
3.10. HBV-Specific CTL Activity
Mouse  splenocytes  from  immunized  mice  were 
stimulated in vitro for 5 days with 10 μg/ml MBP-HBcAg 
and 20 IU/ml recombinant murine IL-2. The restimulated 
splenocytes (5 × 106/mL) were used as effectors. The P815/c 
cell  line  was  used  as  the  target  cell.  P815/c  cells  were 
seeded at 5 × 104 cells/well in 96-well plates and cultured 
for  12  h.  Effector  cells  were  incubated  with  P815/c  at 
various  effector/target  (E/T)  ratios  (12.5:1,  25:1,  or  50:1) 
for 4 h. The HBcAg-specific CTL activity was measured 
by lactate dehydrogenase (LDH) release assay per the 
manufacturer’s  instructions  using  the  CytoTox  96® 
Non-Radioactive Cytotoxicity Assay (Promega, USA). The 
absorbance values from supernatants were recorded at 
OD 450 nm. The percentage of cytotoxicity was calculated 
as follows: [(Experimental release - Effector spontaneous 
release - Target spontaneous release)/(Target maximum 
release - Target spontaneous release)] × 100%.
3.11. Statistical Analysis
Results were expressed as mean ± SD. The statistical 
significance  of  differences  between  2  groups  was 
determined by student’s t-test, and differences between 
2 or more groups were analyzed by one-factor analysis 
of variance (ANOVA). Data were considered statistically 
significant at P < 0.05.
4. Results
4. 1. Construction and Expression of DNA Vaccines
The ubiquitin gene was PCR-amplified from genomic 
DNA from the liver of BALB/c mice, producing a band 
of  552  bp;  splicing  of  the  ubiquitin  and  HBcAg  genes 
by  overlap  extension  generated  a  product  of  780  bp. 
The fragment was purified and cloned into pcDNA3.1 (-). 
Recombinant  plasmids  were  confirmed  by  restriction 
enzyme digestion (Figure 1)  and sequencing. The 
sequences  of  the  DNA  vaccines  were  confirmed  by 
sequencing.  The  expression  of  HBcAg  or  the  fusion 
protein (Ub-HBcAg) was detected by RT-PCR and western 
blot 48 h after the plasmids were transfected into COS-7 
cells. By RT-PCR of pHBcAg transfectants, we amplified 
about a product of approximately 550 bp, consistent with 
the HBcAg gene (552 bp), and a 780-bp product from cells 
that  were  transfected  with  pUb-HBcAg  (Figure 2A). No 
similarly sized bands were seen in the negative control 
RNA.  By  western  blot,  21-kD  proteins  were  expressed 
in the lysates of COS-7 cells that were transfected with 
pUb-HbcAg and pHBcAg. pcDNA3.1 (-) transfectants did 
not express any such proteins. (Figure 2B). These results 
confirm that HBcAg and Ub-HBcAg can be expressed in a 
eukaryotic system.
4. 2. Production of HBc-Apecific Antibody by DNA 
Vaccination
The  anti-HBc  response  that  was  induced  by  the 
vaccines was evaluated by ELISA. At 14 days after priming, 
there  was  no  significant  difference  in  the  endpoint 
titers of anti-HBc between groups. As shown in Figure 
3, robust anti-HBc IgG responses were elicited in mice 
that  were  immunized  with  100  μg  pUb-HBcAg;  the 
endpoint titers of anti-HBc was 1:72,900, 28 d after the 
first immunization. The antibody titers at 28 days were 
significantly higher in the group that was immunized 
with 100 μg pUb-HBcAg versus 100 μg pHBcAg (P = 0.001). 
At 42 days after priming, 100 μg pUb-HBcAg significantly 
enhanced antibody responses compared with pHBcAg 
at the same dose (P < 0.01). The endpoint titers of anti-
HBc in mice that were immunized with pUb-HBcAg 100 
μg  peaked  at  1:656,100  on  Day  42.  No  anti-HBcAg  was 
detected in the serum of control mice that were injected 
with pcDNA3.1 (-). These results indicate that pUb-HBcAg 
enhances humoral immune responses.
4.3. Lymphocyte Proliferation and Cytokine Production 
by Splenocytes from Vaccinated Mice
After 72 h, lymphocyte proliferation was measured by 
CCK-8 assay. Compared with the 100 μg pHBcAg and 50 
μg pHBcAg groups, pUb-HBcAg induced significantly 
greater lymphocyte proliferation (P < 0.01). pHBcAg (100 
μg)  effected  greater  lymphocyte  proliferation  than  50 
μg pHBcAg (P < 0.05). As seen in Figure 4, the pUb-HBcAg 
100  μg  group  experienced  the  greatest  lymphocyte 
proliferation, indicating that vaccination with Ub-fused 
HBcAg induces the proliferation of specific lymphocytes. 
Th1 (IFN-γ,  IL-2)  and  Th2  cytokines  (IL-4,  IL-10)  were 
measured in the supernatants of splenocytes ELISA. pUb-
HBcAg 100 μg and pUb-HBcAg 50 μg induced higher levels 
βHepat Mon. 2011;11(8):620-628
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Figure 1. Electrophoresis of pUb-HBcAg Digested by EcoR I and Hind III
Lane 1: pUb-HBcAg Digested by EcoR I and Hind III; Lane M1: DNA Marker 2000; 
Lane M2: DNA Marker 15000.
1 2 M 3 4 M 5 6 M bp
1000
750
500
250
4 3 2 1
 (B)
 (A)
β-actin
21KD
GAPDH
HBcAg
Figure 2. Expression of the Plasmids
(A) Gene expression of HBcAg and Ub-HBcAg, Lane M: DNA marker 2000; 
Lane 1: blank plasmid pcDNA3.1 (-) transfecting COS-7 cells; Lane 2,3,5: β-actin; 
Lane 4: plasmid pHBcAg transfecting COS-7 cells; Lane 6: plasmid pUb-HBcAg 
transfecting  COS-7  cells.  (B)  Protein  expression  of  HBcAg  (about  21  kDa), 
Lane 1: COS-7 cells transfected with pcDNA3.1 (-); Lane 2 and Lane 3 are the 
same  sample:  COS-7  cells  transfected  with  pUb-HbcAg;  Lane  4:  COS-7  cells 
transfected with pHBcAg
Figure 3. HBcAg-Specific  IgG  Titer  in  the  Sera  of  Mice  Immunized  with 
Various Formulations 
The initial dilution of each serum from immunized mouse was 1:100 and 
followed with serial of three-fold dilution for anti-HBc IgG detection. Data is 
from one representative experiment of three performed and is presented as 
the geometric mean titer ± SD (n = 8). **P < 0.01 pUb-HBcAg 100μg group.
Figure 5. Cytokines Production in the Supernatant of Splenocytes Harvested from Immunized Mice after in Vitro Re-stimulation. Data Represent the Means ± 
SD (n = 8).
Figure 4. The Detection of T Lymphocyte Proliferation Response 
Data shown represent the mean and SD. **P < 0.05, *P <0.01.Hepat Mon. 2011;11(8):620-628
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Figure 7. HBcAg-Specific CTL Activity Was Measured by Lactate Dehydrogenase 
Release Assay
CTL activity is indicated as the mean percentage of specific lysis ± SD at 
different effector:target (E:T) ratios. Experiments were repeated three times 
with similar results. *P < 0.01 pUb-HBcAg 100 μg group vs. pUb-HBcAg 50 μg 
group; **P < 0.05 pUb-HBcAg 50 μg group vs. pHBcAg 100 μg group.
Figure 6. Intracellular Cytokine Expression in Spleen Cells
The whole cell population was doubly stained with fluorescent material labeled using FITC-CD8α and PE-IFN-γ antibodies. The doubly stained cells were counted 
and analyzed by flow cytometry. The data are the mean ± SD from eight mice per group.
of IL-2 than pHBcAg. As shown in Figure 5, IFN-γ levels in 
the  pUb-HBcAg  100  μg  group  were  also  much  higher 
compared with the other plasmids. Compared with pUb-
HBcAg 50 μg (159.8 ± 19.55 pg/mL), pUb-HBcAg 100 μg 
elicited significantly higher production of IFN-γ (185.4 ± 
19.63 pg/mL) (P < 0.05). Mice that were immunized with 
pUb-HBcAg and pHBcAg produced more Th2 cytokines 
(IL-4, IL-10) than the control group (P < 0.01). However, 
Th2 cytokine levels did not differ significantly between 
the pUb-HBcAg and pHBcAg groups.
4. 4. Specific CD8+ T Cells Response
Mice  from  each  group  were  sacrificed,  and 
splenocytes were isolated after the last immunization 
and  restimulated  in  vitro.  Cells  were  doubly  stained 
with  FITC-CD8α and PE-IFN-γ antibodies, counted, and 
analyzed by flow cytometry. IFN-γ expression was higher 
with  pUb-HBcAg  than  in  the  pHBcAg  samples.  The 
percentage of IFN-γ-positive T cells in the CTL population 
was significantly higher with 100 μg pUb-HBcAg versus 
pHBcAg.  (Figure 6).  Thus,  pUb-HBcAg  was  effective  in 
generating CTLs.
4.5. HBcAg-Specific CTL Response 
To evaluate the specific cytotoxicity of T lymphocytes 
in the various groups of immunized mice, the LDH 
relaxation  index  was  measured.  Splenocytes  from 
immunized mice were restimulated in vitro with MBP-
HBcAg and rmIL-2. HBcAg-specific CTL activity at various 
effector/target ratios is shown in (Figure 7). T lymphocytes 
from  mice  that  were  vaccinated  with  pUb-HBcAg  100 
μg killed 52.0 ± 4.5% of target cells at an effector: target 
ratio of 50:1, significantly higher than with pUb-HBcAg 
50 μg (42.0 ± 4.8%) (P < 0.01). pUb-HBcAg 50 μg elicited 
a greater CTL response, compared with pHBcAg 100 μg, 
at an effector:target ratio of 50:1 (P < 0.05). At 25:1, the Hepat Mon. 2011;11(8):620-628
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CTL  response  against  pUb-HBcAg  100  μg  was  higher 
versus the other groups (P < 0.05). These results indicate 
that mice that are immunized with pUb-HBcAg develop 
strong, specific CTL responses.
5. Discussion
Immune responses play a significant role in the 
clearance of hepatitis B virus. Protective immunity 
against HBV depends on both the humoral and 
cellular immune responses. Vigorous polyclonal and 
multispecific immune responses to HBV have been 
detected in acute infections. In contrast, defective CTL- 
and Th cell responses have been observed in patients who 
are chronically infected HBV (16). It has been reported 
that specific cellular immunity against HBV is a key factor 
in the control of HBV infection (26, 27). One promising 
method is the use of DNA vaccines, which have the ability 
to induce antigen-specific cellular immune responses 
(28-30). A DNA vaccine harbors DNA-encoded antigens 
that are subjected to UPS degradation, resulting in 
peptide fragments that can be presented by MHC class I 
antigens to CD8+ T cells, mimicking a microbial infection. 
Although a DNA vaccine can break immune tolerance, it 
is unable to completely eliminate the viral particle load. 
In order to improve the efficacy of DNA vaccines, some 
strategies have been explored (31, 32). In this study, we 
aimed to develop a more powerful HBV DNA vaccine by 
constructing a plasmid that contains both the Ub and 
HBcAg genes.
Ubiquitin is a small, highly conserved regulatory 
protein  that  is  ubiquitous  in  eukaryotes.  The  most 
significant function of ubiquitin in proteolysis is its 
role as a signal for a target protein to be recognized 
and degraded in the proteasome (33). T cell receptors 
recognize short peptides that are presented by MHC class 
I molecules on antigen-presenting cells (34, 35). Higher 
rates of intracellular antigen traffic should increase the 
number and variety of peptides that are available for 
MHC class I binding, increasing the immune response to 
the expressed antigen. A very effective way of improving 
antigenic presentation by DNA vaccination is to fuse 
the Ub gene to the target antigen. A direct correlation 
between  rapid  ubiquitin-mediated  processing  of 
antigens and enhanced cell-mediated immune responses 
has been established (36). It has also become apparent 
that  ubiquitylation  is  a  reversible  reaction,  in  which 
ubiquitin chains are conjugated and deconjugated 
by ubiquitylating and deubiquitylating enzymes, 
respectively (37). To prevent cleavage of the fusion 
gene by deubiquitination enzymes, we constructed an 
expression vector encoding HBcAg fused to Ub, in which 
the C-terminal glycine of Ub was replaced with alanine. 
In addition, the N-terminal Met residue of HBcAg was 
replaced by Arg. Thus, the fusion protein could be quickly 
recognized by the UPS, enhancing HBcAg degradation.
Previous attempts of tagging antigens with ubiquitin 
have placed Arg at the N-terminus to target them for 
rapid processing (38-40). By RT-PCR, the cassettes of the 
Ub-HBcAg constructs were efficiently transcribed, and by 
western blot, HBcAg was translated from the expression 
vectors. As expected, ubiquitin-fused HBcAg converted 
into an excellent substrate for the UPS. We found that 
COS-7 cells that transfected with pUb-HBcAg expressed 
low levels of protein.
The  function  of  our  DNA  vaccines  was  compared 
by  measuring  their  effects  on  immune  responses  in 
BALB/c  mice.  We  found  that  pUb-HBcAg  enhanced  the 
recruitment and activation of T cells and increased the 
number of antigen-specific CD8+/IFN-γ+ T cells. In this 
study, we noted enhanced lymphocyte proliferation in 
mice  that  were  vaccinated  with  ubiquitinated  HBcAg 
compared  with  nonubiquitinated  HBcAg.  This  result 
shows  that  ubiquitin  conjugation  increased  the  cell-
mediated immune response.
Antigen-specific CD8+ T cells play a vital role in the 
control of viral infections. They can remove infected 
target cells through cytotoxic or noncytotoxic activities, 
such as the production of IFN-γ and other Th1 cytokines 
(41). It is believed that Th1 cells primarily secrete IL-2 
and IFN-γ, whereas Th2 cells secrete the type II cytokines 
IL-4  and  IL-10.  We  measured  IL-2,  IFN-γ, IL-10, and IL-4 
in the spleens of mice that were immunized with our 
vaccines.  Mice  that  were  given  ubiquitinated  HBcAg 
expressed  higher  levels  of  IL-2  and  IFN-γ compared 
versus nonubiquitinated HBcAg. T cell-derived cytokines 
can enhance antigen-specific T cell populations. In mice 
that  were  immunized  by  pUb-HBcAg,  the  number  of 
HBcAg-specific CD8+/IFN-γ+ T cells in spleen was higher 
than in pHBcAg recipients, indicating that the immune 
responses are type 1 rather than type 2. The Th1 cell has 
been  reported  to  correlate  with  the  induction  of  CTL 
activity, which is beneficial for viral or tumor eradication 
(42, 43). Inadequate endogenous antigen presentation by 
MHC class I molecules to CD8+ T cells is one of the reasons 
why our immune system fails to eliminate pathogens. 
Patients  with  CHB  or  therapeutic  failure  present  with 
deficient Th1 immunity, associated with inefficient CD8+ 
T  cell  cytotoxicity.  In  our  study,  the  enhancement  of 
antigen presentation increased the number of antigen-
specific CD8+/IFN-γ+T cells in pUb-HBcAg-immunized 
mice. Ubiquitin-fused HBcAg is rapidly degraded by the 
proteasome, resulting in efficient production of a variety 
of peptides, including many CTL epitopes, that might be 
presented by many types of MHC class I molecules.
As shown in Figure 7, mice that were immunized with 
pUb-HBcAg 100 μg showed substantial cytotoxic activity 
against target cells, while those immunized with pUb-
HBcAg 50 μg or pHBcAg showed remarkably enhanced 
cytotoxicity. We have clearly shown that immunization 
a ubiquitin-fuse HBcAg DNA vaccine induces robust 
HBcAg-specific immune responses in BALB/c mice, 
consistent  with  previous  reports  (44,  45).  pUb-HBcAg 
can not only induce cell-mediated immune responses 
but  also  enhance  humoral  immune  responses.  We 
observed very high levels of anti-HBc IgG in mice that Hepat Mon. 2011;11(8):620-628
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were immunized with pUb-HBcAg 100 μg compared with 
other plasmids. These results suggest that pUb-HBcAg 
elicits strong, specific anti-HBc humoral responses in 
BALB/c mice after DNA vaccination. However, in Vidalin’s 
study (46), when ubiquitin was fused to hepatitis C virus 
core antigen, the antibody response was undetectable 
compared with the nonfusion vaccine. This difference in 
result might be attributed to the disparate antigenicities 
of the proteins.
Both pUb-HBcAg and pHBcAg induced humoral and 
cellular immune responses in normal mice, but pUb-
HBcAg  provoked  a  more  robust  response,  suggesting 
that when the Ub gene is fused to the HBcAg gene, the 
efficacy  of  the  DNA  vaccine  increases.  Therefore,  this 
novel strategy may have therapeutic value in infectious 
diseases and cancer.
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